Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Jonathan S ZagerMarlana OrloffPier Francesco FerrucciJunsung ChoiDavid J EschelmanEvan S GlazerAslam EjazJ Harrison HowardErika RichtigSebastian OchsenreitherSunil A ReddyMichael C LoweGeorgia M BeasleyAnja GesierichArmin BenderMartin GschnellReinhard DummerMichel RivoireAna AranceStephen William FenwickJoseph J SaccoSebastian HaferkampCarsten WeishauptJohnny JohnMatthew WheaterChristian H OttensmeierPublished in: Annals of surgical oncology (2024)
Treatment with melphalan/HDS provides a clinically meaningful response rate and demonstrates a favorable benefit-risk profile in patients with unresectable mUM (study funded by Delcath; ClinicalTrials.gov identifier: NCT02678572; EudraCT no. 2015-000417-44).